Ajanta Pharma Limited (BOM:532331)
India
· Delayed Price · Currency is INR | Market Cap | 327.58B |
| Revenue (ttm) | 45.32B |
| Net Income (ttm) | 8.98B |
| Shares Out | n/a |
| EPS (ttm) | 71.57 |
| PE Ratio | 36.49 |
| Forward PE | n/a |
| Dividend | 54.00 (2.05%) |
| Ex-Dividend Date | Nov 6, 2024 |
| Volume | 4,258 |
| Average Volume | 3,757 |
| Open | 2,724.05 |
| Previous Close | 2,728.00 |
| Day's Range | 2,606.05 - 2,724.05 |
| 52-Week Range | 2,049.75 - 3,485.75 |
| Beta | n/a |
| RSI | 48.25 |
| Earnings Date | May 2, 2025 |
About Ajanta Pharma
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited ... [Read more]
Financial Performance
In 2023, Ajanta Pharma's revenue was 42.09 billion, an increase of 12.45% compared to the previous year's 37.43 billion. Earnings were 8.16 billion, an increase of 38.81%.
Financial StatementsNews
Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore
According to IQVIA MAT December 2024 data, Ajanta Pharma’s India growth was 11%, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Ajanta Pharma declares first interim dividend of ₹28 per share for FY25
Ajanta Pharma Ltd. has announced its first interim dividend for the financial year 2024-25. Each share with a face value of ₹2 will receive a dividend of ₹28, totaling an outlay of ₹350 crore. The com...
Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has released its Q2 FY25 results, showcasing a strong performance for the quarter and half-year ending on 30th September 2024. Key H...